Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Helps diagnose bronchial airway hyperreactivity. Sold as Provocholine. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Methacholine Chloride (sold as Provocholine), first approved Oct 31, 1986, with 1 new use approved and 0 published complete response letters.
First approved: Oct 31, 1986
Applications: 1
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $90K
First approved in Japan: Jan 22, 2016
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Provocholine
Part B
$90K
+18%
1,741
Approvals in Japan (PMDA)
First approved in Japan 351 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Provocholine, new ingredientDrugs with a new active ingredient indicated for tests in the diagnosis of bronchial airway hyperresponsiveness. · Santen Pharmaceutical Co., Ltd. · Jan 22, 2016
Clinical Trials
9 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
